Earnings ·
Aktis Oncology, Inc. reported financial results and business highlights for the quarter ended June 30, 2026
AKTSAktis Oncology, Inc.
Aktis Oncology, Inc. reported financial results and business highlights for the quarter ended June 30, 2026. The company held $517.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, compared to $226.8 million at year-end 2025. Collaboration revenue reached $3.4 million, up from $1.6 million in the prior-year period, driven by advancement with Eli Lilly and Company. Research and development expenses increased to $25.3 million from $18.6 million, while general and administrative expenses rose to $7.0 million from $3.9 million. The company reported a net loss of $24.1 million for the quarter. Clinically, Aktis presented first-in-human imaging data for AKY-2519 at ASCO, continued enrollment in the Phase 1b NECTINIUM-2 trial for AKY-1189, and initiated the Phase 1b BActinium-1 trial for AKY-2519 in metastatic castration-resistant prostate cancer. The company operates as a clinical-stage oncology firm focused on developing targeted radiopharmaceuticals using its proprietary miniprotein platform.